More New Cancer Facts in the News: If Your Patient Asks, Part II

A new economic evaluation estimates that semaglutide would need to drop its current price by 81.9% and tirzepatide by 30.5% to be cost effective.

“I think it’s important to have a lot of tools in our toolbox, and [tapinarof cream 1%] is one that gives us great flexibility," said Linda Stein Gold, MD.

The iLet bionic pancreas system conferred an average glucose of less than 183 mg/dL in 97% of adults with T1D in a small study.

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

Your daily dose of the clinical news you may have missed.

Positive findings for postsurgical acute pain relief from the pivotal phase 3 ALLEVIATE-2 trial complete the development program, allowing plans for NDA submission.